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Abstract
Background—Hereditary Breast and Ovarian Cancer (HBOC) syndrome is attributed mostly to
mutations in the Breast Cancer 1 and Breast Cancer 2 genes (BRCA1/2). HBOC is associated with
significantly higher risk for developing breast cancer compared to the general population (55-85%
vs. 12%) and ovarian cancer (20-60% vs. 1.5%). The availability of genetic testing enables
mutation carriers to make informed decisions about managing their cancer risk (e.g., risk-reducing
surgery). However, uptake of testing for HBOC among high-risk individuals is low, indicating the
need to better understand how women decide to pursue genetic testing.
Objective—To evaluate the reliability and validity of the modified Decisional Conflict Scale for
use in decisions associated with genetic testing for HBOC.
Method—In this cross-sectional, cohort study, women were recruited who pursued genetic
testing for HBOC, and also recruited was one of their female relatives who did not pursue testing
from two Genetic Risk Assessment clinics affiliated with a large Comprehensive Cancer Center in
the Midwest. The final sample consisted of 342 women who completed all 16 items of the
Decisional Conflict Scale. The psychometric properties of the scale were assessed using tests of
reliability and validity including face, content, construct, contrast, convergent, and divergent
validity.
Results—Factor analysis using principal axis factoring with oblimin rotation elicited a three-
factor structure (a) Lack of Knowledge about the Decision (a = .97), (b) Lack of Autonomy in
Decision Making (a = .94), and (c) Lack of Confidence in Decision Making (a = .87). These
factors explained 82% of the variance in decisional conflict about genetic testing. Cronbach’s
alpha coefficient was .96.
Discussion—The instrument is an important tool for researchers and healthcare providers
working with women at risk for HBOC who are deciding whether or not genetic testing is the right
choice for them.
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Hereditary Breast and Ovarian Cancer (HBOC) syndrome is the collective term used to
describe genetic susceptibility to breast and ovarian cancer (American Cancer Society
[ACS], 2010). Mutations in the Breast Cancer 1 (BRCA1) and Breast Cancer 2 (BRCA2)
genes account for the majority of these cases. Mutation carriers have significantly higher
risk for developing breast cancer compared to the general population (55-85% vs. 12%) and
ovarian cancer (20-60% vs. 1.5%). Genetic testing for HBOC provides individuals the
opportunity to determine their cancer risk and make decisions potentially to reduce the
occurrence of the syndrome. Patients already diagnosed with breast or ovarian cancer benefit
from knowing their mutation status before making surgical decisions, whereas cancer-free
individuals might use this information to make informed life decisions (e.g., reproduction)
and take proactive steps towards risk management (i.e., increased surveillance,
chemoprevention, and risk-reducing surgery; Eisinger et al., 2001; Finch et al., 2006;
Metcalfe et al., 2008).
However, the use of genetic testing for HBOC among high-risk individuals has been lower
than expected, varying between 26% and 80% (Lerman, Croyle, Tercyak, & Hamann, 2002;
Ropka, Wenzel, Phillips, Siadaty, & Philbrick, 2006), while a significant number of those
who get tested do not seek their results (Pasacreta, 2003). Although research examining how
women decide whether to have genetic testing for HBOC is underway, there has been little
attention to the level of decisional conflict they experience in making this life-altering
decision. The purpose of the current study was to bring attention to this significant topic by
evaluating the psychometric properties of the Decisional Conflict Scale (O’Connor, 1995),
modified to reflect decisional conflict that is specific to genetic testing for HBOC.
Background
Decisional conflict is a condition of hesitation and doubt about a forthcoming decision. It is
defined by several contributing characteristics (i.e., verbalization of uncertainty, fluctuation
between choices, postponed decision-making, stress, self-absorption, and the questioning of
one’s own beliefs). Decisional conflict is influenced by insufficient information concerning
alternative choices and their consequences; lack of decision making skills; and exceeding
demands by significant others (O’Connor, 1993). Individuals with high levels of decisional
conflict about the choice at hand will most likely delay making a decision. Ultimately, high
decisional conflict compromises one’s quality of life (Eastwood, Doering, Roper, & Hays,
2008).
High decisional conflict has been associated with decreased intention to use genetic testing
(Peterson et al., 2006). Decisions to use genetic testing for HBOC likely are influenced by
family characteristics (D’Agincourt-Canning, 2006; Marteau & Weinman, 2006). Linkages
between family processes, family relationships, and the decision to use genetic testing have
been hypothesized (Peterson, 2005; Wilson et al., 2004). Women usually take on the
responsibility of making decisions about genetic testing (Metcalfe et al., 2007) and of
sharing genetic information with family members (Speice, McDaniel, Rowley, & Loader,
2002). Those who refused genetic testing for HBOC found it a more difficult decision to
make and felt pressure from significant others (Claes et al., 2003). Uninformative BRCA1/2
test results led to higher decisional conflict and poorer decisional outcomes among breast
cancer survivors (Rini et al., 2009).
Development of the Decisional Conflict Scale
The original Decisional Conflict Scale (DCS) was developed and tested psychometrically by
O’Connor (1995) with individuals who were making a decision on influenza immunizations
and breast cancer screening. When it was developed, the DCS included three subscales
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derived from the decisional conflict construct, which were named Decision Uncertainty
(three items), Factors Contributing to Uncertainty (nine items), and Perceived Efficacy in
Decision Making (three items; Table 1). Initial psychometric testing of the DCS elicited a
test-retest coefficient of .81 and reliability coefficients of .58 to .92 (O’Connor, 1995).
The original DCS has been adapted widely to measure decisional conflict in patients
deciding to have hormone replacement therapy, colorectal cancer screening, breast cancer
treatment, and treatment of benign prostatic hypertrophy, hypertension, atrial fibrillation,
and patients with schizophrenia. It has been used also in a trial evaluating the efficacy of a
decision aid for HBOC genetic testing (Green et al., 2004) and to measure decisional
conflict about cancer risk management among breast cancer survivors who received an
uninformative BRCA1/2 test result (Rini et al., 2009). Table 2 presents information about
the development and adaptation of the DCS to different populations. However, validity was
not re-evaluated for the adapted DCS; few studies reported reliability data. All studies used
the scale relying on the initial psychometric testing and accepting its properties as initially
reported. When a nonstandardized measure is changed for subsequent use, it is altered into a
different measure and therefore warrants new testing of psychometric properties (Waltz,
Strickland, & Lenz, 2010). Thus, the purpose of the present study was to evaluate the
reliability and validity of the modified DCS for genetic testing for HBOC.
Method
Data Collection Procedures
The scale was administered as part of a survey that examined individual and familial factors
that influence decision-making for HBOC (Katapodi et al., in press). Data for this cross-
sectional cohort study were obtained from two genetic clinics affiliated with a
comprehensive cancer center and a major research-intensive university. The clinics provide
genetic risk assessment, counseling, and genetic testing to individuals at risk for hereditary
cancer syndromes, including HBOC. The study recruited two cohorts of women: (a) women
from the two clinics who had pursued genetic testing for HBOC (Probands), and (b) one of
their female relatives (Relative), who had not pursued testing, although she had a similar
risk of carrying a genetic mutation. Participants were older than 18 years of age and
completed the survey in English.
Briefly, a genetic counselor identified eligible participants by analyzing pedigrees of women
that had genetic testing for HBOC in the clinics within the past 5 years prior to the initiation
of the study. Eligible Probands were sent an invitation letter, tailored to identify their high-
risk relatives (e.g., sister, maternal or paternal aunt). After Probands agreed to participate in
the study, they were mailed a self-administered survey, along with an invitation letter for
their high-risk relative. Relatives who agreed to participate were mailed a similar survey.
Data collection occurred from January 2008 through April 2009. The Institutional Review
Board of the university and the Protocol Review Committee of the cancer center approved
the study.
Measures
Members of participating dyads (Proband Relative) were each mailed a 25-page, self-
administered survey that captured demographic information; personal and family history of
genetic testing and breast or ovarian cancer; perceived risk of HBOC; perceived utility of
genetic testing (benefits minus barriers of genetic testing); knowledge about the genetics of
HBOC; and decisional conflict about genetic testing for HBOC. Perceived risk was assessed
with 19 items assessing absolute and comparative perceptions of risk of developing breast
and ovarian cancer. These items were developed previously and validated with a sample
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including 15% of women at high risk for HBOC (Katapodi, Dodd, Lee, & Facione, 2009).
Three additional items were developed for this study: “How informed are you about your
HBOC risk?” “How much do you know about HBOC?” and “How much control you feel
you have over your HBOC risk?” Perceived utility of genetic testing was assessed using
seven items for Perceived Benefits of genetic testing and eight items for Perceived Barriers
of genetic testing for HBOC (Jacobsen, Valdimarsdottir, Brown, & Offit, 1997). A
composite score from the two subscales creates a measure of perceived utility of genetic
testing.
Decisional Conflict Scale--Genetic Testing HBOC
The items used in the DCS--Genetic Testing for HBOC were adapted from the original DCS
(O’Connor, 1995). All 16 items were scored on a five-point Likert scale, and were changed
to a positive wording format so that a higher score would indicate higher decisional conflict.
When participants were given the DCS-Genetic Testing HBOC, they were instructed to
“Think about the choice to have genetic testing for HBOC” and then to check the box
indicating their degree of agreement with each statement. Each box was grounded with the
worded Likert response. The Likert scale was coded with 1 = strongly disagree, 2 =
disagree, 3 = neither agree nor disagree, 4 = agree, and 5 = strongly agree.
Procedures for Data Analyses
The suitability of the sample size was examined prior to analyses. Due to the small number
of missing responses, it was determined a priori that those participants who had omitted
questions on the DCS-Genetic Testing HBOC would be excluded from data analyses. This
resulted in complete data from 342 participants who were included in the study. As a general
rule of thumb, Tabachnick and Fidell (2007) recommend having at least 300 cases for factor
analysis. Nunnally and Bernstein (1994) suggested having 10 cases per item in the
instrument for factor analysis. Thus, with 16 items in the DCS-Genetic Testing HBOC and
342 participants, an sample size was achieved also for factor analysis. Sampling adequacy
for factor analysis was determined using the Kaiser-Meyer-Olkin (KMO) and the Bartlett
test. The KMO measure of sampling adequacy was .93, indicating a “marvelous” sample for
factor analysis (Kaiser, 1974, p. 35). The Bartlett’s Test of Sphericity was significant (c2 =
6444.17, p < .001), indicating that relationships among the items existed (Tabachnick &
Fidell, 2007).
All data analyses procedures were undertaken using SPSS, version 17.0. Factor analysis was
applied to consolidate items and identify the factors within the DCS-Genetic Testing HBOC.
The construct validity of the DCS-Genetic was examined using principal axis factoring
(PAF) with oblimin rotation. Additional correlational analyses were completed to ascertain
the presence of contrast, convergent, divergent, and predictive validity of the revised
measure.
Results
Participants
The sample consisted of 200 Probands and 172 Relatives. Only 354 of the 372 completed
the DCS-Genetic Testing HBOC. The mean age of the sample was 49.6 ± 13.6 years,
ranging from 18 to 81 years. Most participants (95.7%) reported having health insurance.
The demographics of the sample are described in more detail in Table 3. Overall, the sample
included women who were primarily Caucasian, well-educated, married or partnered, and
were of high socioeconomic status.
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Inter-item Correlations
The inter-item correlations were assessed for the existence of conceptual redundancy. First,
the correlation matrix was inspected for values that were lower than .30; none were
identified. However, one value above .90 was noted. The items “I feel I know the pros of
each option” and “I feel I knew the cons of each option” were correlated at .92. Factor
analysis was run with both of these items included and then with each deleted. The decision
was made to include both of these items because they examine the perceived risks and
benefits of genetic testing, they improved factor structure, and they increase the applicability
of the model to those who may have more or less favorable opinions about genetic testing
for HBOC.
Reliability
The internal consistency of the DCS-Genetic Testing HBOC was evaluated. The reliability
coefficient should be .80 or greater for an instrument that has previously been tested
(Nunnally & Bernstein, 1994). In this study, items were reworded to capture the content of
genetic testing for HBOC and were re-stated in positively worded items. After these
changes, the Cronbach’s alpha coefficient for the DCS-Genetic Testing HBOC was .96,
which is excellent for what is considered by Waltz, Strickland, and Lenz (2010) to be a new
scale.
Validity
The types of validity used in assessing the DCS-Genetic Testing HBOC were face,
construct, contrast, convergent, divergent, and predictive validity (Table 5).
Face validity—Face validity “is not validity in the true sense and refers only to the
appearance of the instrument to the layperson” (Waltz, Strickland, & Lenz, 2010, p. 166).
The DCS-Genetic Testing HBOC is an easy to read, well-spaced scale, with minimal
wording, and is presented to the participant on one page. The reading level of the DCS was
cited by O’Connor (1995) as being at an eighth grade level. The DCS-Genetic Testing
HBOC has a Flesch-Kincaid Reading Level of six, indicating that participants with a sixth
grade education or higher would be able to read and complete the scale (Flesch, 1948;
Kincaid, Fishburne, Robers, & Chissom, 1975).
Construct validity—The 16 items in the DSC-Genetic Testing HBOC were examined
with various exploratory factor analysis methods. Principal component analysis (PCA) with
varimax and oblimin rotation, PAF with varimax and oblimin rotation, maximum likelihood
factor extraction, and unweighted least squares factoring were conducted to determine the
best factor solution. Prior to beginning the factor analysis, values were preset for analysis.
The criteria that determined the number of factors and the number of items within a factor
have been outlined by Nunnally and Bernstein (1994) and include (a) the point of
discontinuity of the scree plot, (b) an eigenvalue greater than 1, and (c) item factor loading
greater than .40. After multiple iterations, PAF with oblimin rotation was determined to
elicit the best factor solution. The three-factor solution that resulted from this exploratory
factor analysis was consistent with the number of factors displayed in the scree plot and with
factors having an eigenvalue of greater than one.
This analysis elicited three factors, named Lack of Knowledge About the Decision (seven
items), Lack of Autonomy in Decision Making (six items), and Lack of Confidence in
Decision Making (three items). The total variance of decisional conflict in the context of
genetic testing for HBOC explained by the three factors was 81.57%. The reliabilities of the
new subscales were assessed and were found to be satisfactory, with a range of .87-.97
(Table 6). The pattern matrix and structure matrix (Pallant, 2007) are demonstrated in Table
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7. There were no items that loaded on more than one component at .40 or greater. Although
the DCS–Genetic Testing for HBOC includes the 16 items of the original DCS, two items
loaded on a different factor. The two items are used to examine perceived pressure and
perceived support from significant others in the decision to use genetic testing for HBOC.
These two items loaded on the Lack of Autonomy in Decision Making factor, instead of
Factors Contributing to Uncertainty of the original DCS (Table 7). These new factor
loadings demonstrate that the adapted DCS–Genetic Testing for HBOC includes one of the
original subscales and two new subscales. This finding suggests that decisional conflict for
genetic testing is markedly distinct from decisional conflict in other healthcare decisions.
Contrast validity—Contrast validity assesses the differences measured by an instrument
between two or more diverse groups. Contrast validity was determined using an independent
t-test between the cohort of Probands, who used genetic testing, and the cohort of female
Relatives, who did not. The hypothesis being tested was that there would be differences
between the two groups on the decisional conflict they faced when considering genetic
testing. As hypothesized, the t-test revealed significant differences (p < .001) between the
Probands and their Relatives on all factors (Lack of Knowledge About the Decision, Lack of
Autonomy in Decision Making, and Lack of Confidence in Decision Making) and total
scores for the DCS-genetic (Table 8).
Convergent validity—Convergent validity is established through a significant correlation
with another item or instrument that measures the same construct (Tabachnick & Fidell,
2007). Convergent validity was tested using each factor independently and correlating it
with items from the Perceived Risk Questionnaire used in the study. First, the correlation
between an item inquiring “How informed are you about your HBOC risk?” and Factor 3,
Lack of Confidence in Decision Making, was assessed. A significant negative correlation
was found (r = -.31, p < .001), indicating that the more informed an individual feels, the
higher their confidence in making decisions. Second, the correlation between an item
inquiring “How much do you know about HBOC?” and Factor 1, Lack of Knowledge in
Decision Making, was evaluated. A significant negative correlation was found (r = -.47, p
< .001), indicating that knowledge about HBOC decreases perceived lack of knowledge in
decision making. Finally, the correlation between an item inquiring “How much control you
feel you have over your HBOC risk?” and Factor 2, Lack of Autonomy in Decision Making,
was determined. A small but significant negative correlation was found (r = -13, p < .05)
indicating that the more conflict an individual reported with autonomy, the less control they
felt they had in decision making. These correlations are congruent with the theory of
decision making and the construct of decisional conflict. Insufficient information about the
problem at hand and alternative options; lack of decision making skills; and demands by
significant others are factors contributing to increased decisional conflict (O’Connor, 1993).
Divergent validity—An instrument’s divergent validity is assessed by its low correlation
with a scale or item that measures a different construct (Tabachnick & Fidell, 2007).
Divergent validity was tested using the total score of the DCS-Genetic Testing HBOC and
an item from the Perceived Utility of Genetic Testing (PUGT) scale (Jacobsen,
Valdimarsdottir, Brown, & Offit, 1997), which assesses an individual’s view on the
usefulness of genetic testing. An item from the PUGT scale asks whether “genetic testing
will ease my mind regardless of the test result” with a Likert score of 1 = strongly disagree
to 5 = strongly agree. A significant negative correlation (r = -.30, p < .01) was found
between the DCS-Genetic Testing HBOC total score and this item from the PUGT scale.
Thus, decisional conflict is decreased by the belief that genetic testing will ease an
individual’s mind, which is theoretically congruent with the construct of decisional conflict.
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Predictive validity—Predictive validity is used to assess an instrument’s ability to
estimate some form of behavior (Nunnally & Bernstein, 1994). Predictive validity of the
DCS-Genetic Testing HBOC was evaluated with the instrument’s ability to predict whether
an individual would pursue prophylactic measures to reduce their HBOC risk. Significant
correlations were found between the total score of the DCS-Genetic Testing HBOC and
items inquiring whether women “had a prophylactic mastectomy” (r = .20, p < .001) and
whether they “had a prophylactic oophorectomy” (r = .24, p < .001). These correlations
indicate that women with higher decisional conflict who were considering prophylactic
surgery as a means of reducing their HBOC risk were likely more ambivalent about the
implications of the test result for their own health.
Discussion
Using psychometric testing of the DCS-Genetic Testing HBOC, it was determined that all
16 items should remain in the scale. The analysis elicited a three-factor solution utilizing
PAF with oblimin rotation. The three-factor solution provided evidence that Lack of
Knowledge About the Decision, Lack of Autonomy in Decision Making, and Lack of
Confidence in Decision Making are factors that contribute to women’s decisional conflict
about genetic testing for HBOC. The three-factor solution explained 81.57% of the variance
in decisional conflict; the reliabilities of the new factors ranged from .87-.97, which
demonstrate an instrument with a high amount of variance explained and strong reliability
coefficients.
Although the DCS–Genetic Testing for HBOC contains the 16 items included in the original
DCS developed by O’Connor, two items loaded on a different factor. These two items
examine perceived pressure and perceived support in the decision to pursue genetic testing.
The different item loadings demonstrate that decisional conflict about genetic testing is
inherently distinct from decisional conflict about influenza vaccination and disease
treatment. The new factor loadings support hypotheses about intra-familial decision-making
processes that are paramount in the context of HBOC and reflect the hypothesized
contextual dynamics that influence autonomy in decision making for genetic testing
(Peterson, 2005; Wilson et al., 2004).
Limitations
One limitation of this study was the homogeneous sample. Participants were mostly
Caucasian women of high educational and socioeconomic status; therefore, their decisional
conflict may be different from women of other ethnicities, educational levels, and
socioeconomic status. Thus, future research should evaluate this scale in a more diverse
group of women. However, genetic mutations that predispose to HBOC are more common
among specific Caucasian subgroups (i.e., Ashkenazi Jewish, Icelandic, French-Canadian,
Swedish, Hungarian; ACS, 2010). Thus, although our sample was homogenous, it was
representative of women who seek genetic testing in the two high-risk clinics, supporting the
relevance of these results to the general population at high risk for HBOC. A second
limitation is that history of prophylactic surgery was based on self-report and may not be
accurate. Finally, the retrospective and cross-sectional study design limited the ability to
capture the dynamics of the decision-making process at the time that the actual decision for
genetic testing was being made. Despite its limitations, the study included a large sample (n
= 372) of women at various levels of risk for HBOC. Moreover, the recruitment method
allowed for comparison of two related cohorts of women, namely Probands who pursued
genetic testing and their high-risk Relatives who did not.
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Clinical Implications
Attending to women’s decisional conflict about genetic testing for HBOC should be a
priority in clinical practice. Rini et al. (2009) reported that a substantial proportion of breast
cancer survivors who received uninformative BRCA1/2 test results had high decisional
conflict scores and were at risk for poor decisional outcomes. They also reported that
women who were considering risk-reducing mastectomy or oophorectomy experienced
higher decisional conflict than women who did not consider these options. This is consistent
with the positive correlations between DCS-Genetic Testing HBOC and uptake of
prophylactic mastectomy and prophylactic oophorectomy reported in this study. Together,
these findings have important clinical implications. Decisions for life-altering surgery, such
as prophylactic mastectomy and oophorectomy, are difficult to make especially among
asymptomatic women who are at high risk for HBOC. These women are likely to experience
lingering dissatisfaction and lack of confidence in their decisions for HBOC genetic testing
and risk management. The present study made a contribution in this clinical area by
evaluating the psychometric properties of the DCS-Genetic Testing for HBOC. The scale is
an important tool for researchers and healthcare providers who are working with women
trying to decide whether genetic testing is the right choice for them. The scale can identify
women who experience high decisional conflict, so they can receive more clinical attention
and decisional support.
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Table 1
Subscales and Items of the original Decisional Conflict Scale
Subscale Items
Decision Uncertainty Subscale 1. This decision is easy for me to make
2. I’m unsure what to do in this decision
3. It’s clear what choice is best for me
Factors Contributing to Uncertainty Subscale 4. I’m aware of the choices I have to
5. I feel I know the benefits of
6. I feel I know the risks and side effects of
7. I know how important the benefits are to me in this decision
8. I know how important the risks and side effects are to me in this decision
9. It’s hard to decide if the benefits are more important to me than the risks, or if the risks
are more important than the benefits
10. I feel pressure from others in making this decision
11. I have the right amount of support from others in making this choice
12. I need more advice and information about the choices
Perceived Efficacy in Decision Making Subscale 13. I feel I have made an informed choice
14. My decision shows what is important to me
15. I expect to stick with my decision
16. I am satisfied with my decision
Notes. The original Decisional Conflict Scale was printed in O’Connor, 1995. Item loadings were not provided in the original article.
Nurs Res. Author manuscript; available in PMC 2012 November 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Katapodi et al. Page 12
Table 2
Development of the Decisional Conflict Scale
Study (in chronological order) Population Reliability*
O’Connor, 1995 Influenza-immunization: Test-retest coefficient = .81
1. health science students (n = 151)
2. health employees (n = 15)
3. respiratory or cardiac patients (n = 283)
Breast-cancer-screening: Cronbach alpha for total scale
ranged .78 - .92
1. random sample, women ages 50-69 (n = 386)
Bunn & O’Connor, 1996 Schizophrenic patients (n = 94) Cronbach
alpha = .78
O’Connor et al., 1998 Postmenopausal women ages 50-69 years (n = 165) None reported
O’Connor et al., 1999 Postmenopausal women ages 50-69 years, who had not used
hormone replacement therapy (n = 201)
None reported
Man-Son-Hing et al., 1999 Patient’s with a history of atrial fibrillation and low risk of stroke
(n = 287)
Cronbach
alpha = .92
Dodin, Légaré, Daudelin, Tetroe, &
O’Connor, 2001
Menopausal Francophone women, ages 45-69 years (n = 101) In French,
Cronbach alpha = .70
Goel, Sawka, Thiel, Gort, &
O’Connor, 2001
Patients with newly diagnosed stage I or II breast cancer, had not
undergone surgical treatment (n = 136)
None reported
Murray et al., 2001 Men with benign prostatic hypertrophy (n = 112) None reported
Murray et al., 2001 Women considering hormone replacement therapy (n = 205) None reported
Dolan & Frisina, 2002 Internal medicine patients at average risk for colorectal cancer (n =
93)
Cronbach
alpha = .97
Légaré et al., 2003 1) Physicians (n = 40)
2) Postmenopausal women (n = 184)
Cronbach
alpha = .93
Montgomery, Fahey, & Peters, 2003 Patients newly diagnosed with hypertension (n = 217) None reported
Whelan et al., 2004 Women with newly diagnosed clinical stage I or II breast cancer
who had not received surgical treatment (n = 201)
None reported
Hunter et al., 2005 Women ages ≥35 years undergoing prenatal diagnosis (e.g.,
amniocentesis; n = 352)
None reported
McAlister et al., 2005 Nonvalvular atrial fibrillation patients (n = 434) None reported
Shorten, Shorten, Keogh, West, &
Morris, 2005
Pregnant women (n = 227) Cronbach
alpha = .63 at 28 weeks & .67 at
36 weeks
Laupacis et al., 2006 Cardiac patients (n = 120) None reported
Notes. The only study that examined validity of the Decisional Conflict Scale was the original study by O’Connor (1995).
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Table 3
Demographic Characteristics (n =372)
Characteristics n %
Group Proband 200 53.8
Female Relative 172 46.2
Ethnicity Caucasian 343 92.2
African American 6 1.6
American Indian 5 1.4
Other a 6 1.6
Missing 12 3.2
Marital Status Married/ Partnered 264 71.0
Single 45 12.1
Divorced/Separated 36 9.7
Widowed 18 4.8
Missing 9 2.4
Education High School or less 41 11.0
Some College/Associates Degree 104 28.0
Bachelor’s Degree 112 30.0
Graduate Degree b 115 31.0
Income Less than $20,000 27 7.3
$21,000 - $40,000 46 12.4
$41,000 - $60,000 64 17.2
$61,000 - $80,000 48 12.9
$81,000 - $100,000 56 15.0
More than $100,000 121 32.5
Missing 10 2.7
Notes.
a
Includes Hispanic, Asian American, and Arab American
b
Includes Master’s Degree, Professional Degree, or Doctoral Degree
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Table 4
Item Analysis Decisional Conflict Scale - Genetic Testing Hereditary Breast and Ovarian Cancer
Item M SD
1. This decision is easy for me 2.19 1.07
2. I’m sure what to do 2.32 1.10
3. It’s clear what choice is best 2.14 .96
4. I’m aware of the options I have 1.98 .89
5. I feel I know the pros of 2.08 .91
6. I feel I know the cons of 2.14 .93
7. I am clear about how important the pros are to me 2.03 .87
8. I am clear about how important the cons are to me 2.15 .94
9. For the main option I am considering, I am clear about 2.15 .90
10. I am making this choice without any pressure 1.73 .72
11. I have the right amount of support from others 1.77 .72
12. I have enough advice about 2.10 .94
13. I feel I have made an informed 1.94 .83
14. My decision shows what is important 1.88 .75
15. I expect to stick with 1.86 .75
16. I am satisfied with 1.86 .76
Total 32.31 11.36
Notes.
Cronbach’s alpha for the Decisional Conflict Scale–Genetic Testing for Hereditary Breast and Ovarian Cancer = .96
The instrument is available from the corresponding author.
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Table 5
Types of Validity used to Validate the Decisional Conflict Scale – Genetic Testing Hereditary Breast and
Ovarian Cancer
Validity Definition Testing
Face The appearance of the scale Presented on one page. Flesch-Kincaid Reading Level of six.
Content Scale assesses a content
domain
DCS has already been assessed for content validity and utilized in different populations. Content
validity was not assessed.
Construct Scale measures what it
purports to measure
Three factors elicited: Lack of Knowledge about the Decision (seven items), Lack of Autonomy
in Decision Making (six items), and Lack of Confidence in Decision Making (three items).
• Three components reflected theoretical congruence
• No items loaded on more than one component at .40 or greater
• The total explained variance was 81.57%
Contrast Assess differences in ≥2
groups
Independent t-test between Probands (used genetic testing), and Relatives (did not use genetic
testing); differences (p < .001) on all factors and total scores for the DCS-genetic.
Convergent Correlation with another
scale that measures same
construct
• “How informed do you feel about your HBOC risk” and Factor 3, Lack of Confidence
in Decision Making (r = -.31, p < .001).
• “How much do you know about HBOC” and Factor 1, Lack of Knowledge in
Decision Making (r = -.47, p < .001).
• “How much control you feel you have over your HBOC risk” and Factor 2, Lack of
Autonomy in Decision Making, (r = -13, p < .05).
Divergent Negative correlation with
scale that measures
different construct
Total score of the DCS-Genetic Testing HBOC and “genetic testing will ease my mind regardless
of the test result” from the Perceived Utility of Genetic Testing scale, (r = -.30, p < .01)
Concurrent Agreement between scale
and a validated scale that
measures the same
construct
No other instrument to measure decisional conflict was used. Concurrent validity was not
assessed.
Predictive Ability to predict some
form of behavior
Total score of the DCS-Genetic Testing HBOC and items inquiring whether women had “…a
prophylactic mastectomy” (r = .201, p < .001) and “… a prophylactic oophorectomy” (r = .244, p
< .001).
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Table 6
Mean, Standard Deviation, and Internal Reliabilities for the Three Newly Derived Subscales
New Subscale M SD a
Factor 1: Lack of Knowledge about the Decision (items 4, 5, 6, 7, 8, 9, 12) 14.61 5.81 .97
Factor 2: Lack of Autonomy in Decision Making (items 10, 11, 13, 14, 15, 16) 11.05 3.97 .94
Factor 3: Lack of Confidence in Decision Making (items 1, 2, 3) 6.65 2.80 .87
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